register free | resend password

Pressemitteilungen zu dem Thema clinical trial


Unterkategorien

PresseMitteilungen zu dem Schlagwort clinical trial


CROS NT Launches CROScheck(TM) at DIA Chicago to Help Clinical Trial Sponsors Meet New ICH GCP E6(R2) Guidelines

CHAPEL HILL, NC -- (Marketwired) -- 06/20/17 -- CROS NT, a global Clinical Research Organization (CRO), today announced CROScheck™, a clinical trial solution to deliver Sponsors the biometrics oversight needed to assess data integrity from multiple sites. By incorporating data management and statistical methodology along with technology, Sponsors can take a modular or full risk-based approach.DIA attendees are encouraged to visit CROS NT at DIA Booth #1040 to learn more about how CROScheck addr ...


20.06.2017

PAREXEL introduces its Connected Journey™ of newly integrated data-driven services to simplify drug development and commercialisation

LONDON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, is launching its Connected Journey™ of data-driven services. This newly integrated network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology, processes, and expertise to deliver critical intelligence suppo ...


19.06.2017

PAREXEL Collaborates With Sanofi To Advance The Use Of Wearable Devices In Life Science Industry

LONDON, June 15, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials. Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’ ability to participate, driving patient engagement, and creating more opportunities for decentra ...


15.06.2017

Mark Paul appointed President of CROS NT LLC

CHAPEL HILL, NC -- (Marketwired) -- 05/30/17 -- CROS NT announced today that Mark Paul has been appointed President of the company''s North American operations effective June 1, 2017. Paul brings a wealth of operational and commercial experience to the role and most recently has been serving as Senior Vice President of Program Management for CROS NT."Mark is the perfect candidate for what is an important role within the business. He has a strong customer focus and a great underst ...


30.05.2017

UPDATE - CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC -- (Marketwired) -- 05/24/17 -- CROS NT today announced the go-live of its RaveX team in an extension of the company''s partnership with .Under the partnership, CROS NT will offer its customers -- the latest generation of Medidata''s industry-leading EDC system, Medidata Rave-- as well as Medidata''s randomization and trial supply management (RTSM) system, . The Data Management division in CROS NT offers Sponsors of c ...


24.05.2017

CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC -- (Marketwired) -- 05/23/17 -- CROS NT today announced the go-live of its RaveX team in an extension of the company''s partnership with .Under the partnership, CROS NT will offer its customers -- the latest generation of Medidata''s industry-leading EDC system, Medidata Rave-- as well as Medidata''s randomization and trial supply management (RTSM) system, . The Data Management division in CROS NT offers Sponsors of c ...


23.05.2017

Desert Oasis Healthcare Establishes Center for Research and Healthcare Innovation Featuring Altura''s HCP Studies(TM) Mobile Platform

MISSION VIEJO, CA and PALM SPRINGS, CA -- (Marketwired) -- 04/19/17 -- Desert Oasis Healthcare (DOHC), a California-based Physician Group within the Heritage Provider Network, today announced the establishment of a Center for Research and Healthcare Innovation (DCRI). Created in collaboration with partner Altura, the DCRI is designed to build upon the long-standing clinical trial resources at DOHC. By implementing Altura''s Study Engagement Platform™, DCRI will expand DOHC'' ...


19.04.2017

PAREXEL Launches Patient Sensor Solution To Transform Clinical Trial Data Collection

LONDON, March 30, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of its patient sensor solution, a new offering that securely captures, transmits, stores, and visualises study subject data in clinical trials. PAREXEL’s offering, powered by the Perceptive MyTrials® Analytics platform, enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via med ...


30.03.2017

CROS NT Acquires Clinical Division of PM Clinical to Expand Service Offering

CHAPEL HILL, NC and MAIDENHEAD, UNITED KINGDOM -- (Marketwired) -- 03/07/17 -- CROS NT today announced the acquisition of the clinical division of PM Clinical Limited, a sister company under the PM Holding entity currently based in the United Kingdom and Italy.The move expands CROS NT''s service offerings by adding regulatory consultancy, study design, feasibility, clinical project management and monitoring. The acquisition shifts CROS NT from a biometrics-only CRO to a niche provider ...


07.03.2017

Bacterial Conjunctivitis Global Clinical Trials by End Point Status

Albany, New York, January 20, 2017: Market Research Hub has recently announced the addition of a new report to it broad database titled as “Bacterial Conjunctivitis Global Clinical Trials Review, H2, 2016”. This report provides top line data relating to the clinical trials on Bacterial Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type= ...


20.01.2017

Amedica Announces Pricing of Public Offering to Raise $4.5 Million

SALT LAKE CITY, UT -- (Marketwired) -- 01/19/17 -- Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.51 for one share of common stock and 0.45 warrants. Each whole warrant is exercisable for one share of common stock. The Company expects to receive gross proceeds of approximately $4.5 million, before deducting under ...


19.01.2017

RespireRx Pharmaceuticals Inc. to Present at 9th Annual Biotech Showcase(TM) 2017

GLEN ROCK, NJ -- (Marketwired) -- 01/06/17 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for the treatment of respiratory disorders, particularly sleep apneas and drug-induced respiratory depression for which there are no approved pharmaceuticals, announces that the Company''s President, Chief Executive Officer and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present ...


06.01.2017

Reflexion Interactive Technologies to Showcase The Reflexion Edge at CES Las Vegas

LAS VEGAS, NV -- (Marketwired) -- 01/03/17 -- Reflexion Interactive Technologies will exhibit The Reflexion Edge, a portable concussion detection machine, at CES in Las Vegas, Nevada January 5 - 8 at the Las Vegas Convention. Reflexion will be part of the Case Western Reserve University Booth #51102 in the University Innovations Section in the Sands Expo Center."We are looking forward to showcasing our new patent pending prototype of the Reflexion Edge, a robust concussion monitoring syste ...


03.01.2017

Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

LOS ANGELES, CA -- (Marketwired) -- 12/21/16 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel which per ...


21.12.2016

RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression

GLEN ROCK, NJ -- (Marketwired) -- 12/15/16 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression announces data for its CX1739 clinical study in opioid induced respiratory depression.Arnold Lippa, Ph.D., Executive Chairman and Chief Scientific Officer commented, "We are pleased with the positive results of our recen ...


15.12.2016

Stellar Board Member and Pharma Expert to Join Executive Team

LOS ANGELES, CA -- (Marketwired) -- 10/24/16 -- Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer''s and lupus, among other diseases, announced today that Gregory T. Baxter, PhD, will join the company''s management team in the new role of Executive Vice President of Corporate Development, effective December 1, 2016.Dr. Baxter, a current mem ...


24.10.2016

Quanticate Names Alan Morgan Chief Operating Officer

LONDON, UNITED KINGDOM and RESEARCH TRIANGLE PARK, NC -- (Marketwired) -- 10/04/16 -- , a leading global data-focused (CRO) today announced that it has named Alan Morgan as the company''s Chief Operating Officer. Reporting to Quanticate''s Chairman and Chief Executive Officer David Underwood, Morgan will work across Quanticate''s global office network (UK, US, India, South Africa, and Poland) to build and expand upon the company''s reputation for outstan ...


04.10.2016

Governor Brown Signs Into Law the California Cancer Clinical Trials Program

SACRAMENTO, CA -- (Marketwired) -- 09/29/16 -- Earlier this week, Governor Jerry Brown signed into law the new California Cancer Clinical Trials Program to increase access to cancer clinical trials for patients, especially women and under-represented communities. This makes the State the first in the country to legally recognize the financial burdens afflicting cancer patients seeking treatment in clinical trials. The bill was sponsored by Lazarex Cancer Foundation, authored by Assemblymember S ...


29.09.2016

UPDATE - RespireRx Pharmaceuticals Inc. Announces Preliminary Top-Line Analysis of Data From Duke University Phase 2A Clinical Trial of CX1739

GLEN ROCK, NJ -- (Marketwired) -- 09/12/16 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPID) (OTCQB: RSPI) ("RespireRx" or the "Company") is a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression (RD) and sleep apneas.RespireRx is today reporting preliminary top-line data from its Phase 2A clinical trial of CX1739, the Company''s proprietary, orally administered ampakine. CX1739 was determined to be safe and ...


13.09.2016

RespireRx Pharmaceuticals Inc. to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 12, 2016

GLEN ROCK, NJ -- (Marketwired) -- 09/08/16 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company''s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Rodman & Renshaw 18th Annual Global Investment Conference () at the Lotte Ne ...


08.09.2016

NovaRx Raises Capital, Changes Name to Activate Immunotherapy and Expands Management Team

SAN DIEGO, CA -- (Marketwired) -- 08/15/16 -- NovaRx, a cancer immunotherapy company with an innovative treatment that has been tested in late stage clinical trials in over 500 patients, today announced that it has closed the first tranche of a multi-million dollar financing and expanded its management team to rapidly advance its programs and strengthen its proprietary position. In conjunction with these events, NovaRx is changing its name to Activate Immunotherapy ("Activate" or the ...


15.08.2016

Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility

VANCOUVER, BC -- (Marketwired) -- 06/28/16 -- . (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "" or ""), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases, is holding a press conference today to announce plans for the commencement of the company''s clinical trial program at Innovation ...


28.06.2016

Oracle Announces Pfizer''s Selection of Oracle Cloud for Clinical Data Management and Trial Management Across Its Clinical Trial Portfolio

REDWOOD SHORES, CA -- (Marketwired) -- 06/20/16 -- Oracle today announced that after a detailed review and selection process, Pfizer has selected Oracle Health Sciences InForm Cloud Service and the Oracle Siebel Clinical Trial Management and Monitoring Cloud Service to help manage and monitor its more than 300 clinical trials a year and continue to provide best-in-class solutions."Oracle Health Sciences InForm Cloud Service and Oracle Siebel Clinical Trial Management and Monitoring Cloud S ...


20.06.2016

RespireRx Pharmaceuticals Inc. Files March 31, 2016 Quarterly Report on Form 10-Q

GLEN ROCK, NJ -- (Marketwired) -- 05/16/16 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its March 31, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company''s ongoing clinical trials, financing activities and its plans for the remainder of 2016.James S. Manuso, ...


16.05.2016

Application of Fish Skin to Open Wounds Improves Healing

BREMEN, GERMANY -- (Marketwired) -- 05/06/16 -- Kerecis, the company using Omega3-rich fish skin to heal human wounds and tissue damage, will present results of human and laboratory trials at the European Wound Management Symposium (EWMA) May 11-13 at the Bremen Messe in Germany. Kerecis is exhibiting in Booth 1A 05.In one trial, the fish-skin treatment resulted in a 39 percent reduction in the use of antibiotics. Another trial showed superior cell ingrowth using the fish-skin treatment compare ...


06.05.2016

Research Hive Introduces Unprecedented Recruiting and Retention Tool for Clinical Trial Management

ATLANTA, GA -- (Marketwired) -- 04/16/16 -- Research Hive, a software developer for clinical research professionals, has announced the recent release of their to help research sites and trial sponsors run clinical trials more efficiently. Research Hive will debut the software at the Association of Clinical Research Professionals (ACRP) Meeting & Expo, April 16-19 at the Georgia World Congress Center in downtown Atlanta."We are thrilled to invite the public to demo our software at ACRP ...


16.04.2016

Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI) for Ulcerative Colitis

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/06/16 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune response, announced it has been awarded funding of $240,000 from Genome British Columbia (Genome BC) to support a Phase 2a clinical trial of Qu Biologics'' QBECO SSI for the treatment of moderate-to-severe ulcerative colitis (UC).In this study, Qu Biologics will investigate the safety, efficacy a ...


06.04.2016

Nextrials'' Jim Rogers Discusses EHR Integration Technology With Northern California Clinical Research Professionals

SAN RAMON, CA -- (Marketwired) -- 03/21/16 -- Jim Rogers, CEO of ., a leader in clinical research software and services, will discuss how clinical researchers can benefit from data integration with electronic health record technology at an upcoming meeting of the Northern California Chapter of the Association of Clinical Research Professionals (NCC ACRP). On March 23 at the headquarters for Genentech in San Francisco, Rogers will present the various benefits associated with using the company� ...


21.03.2016

Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn''s Disease Clinical Trial

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 03/21/16 -- ., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory diseases, announced initial results from the QBECO-01 study, a 68-patient randomized, placebo-controlled clinical study for the treatment of moderate-to-severe Crohn''s disease.Based on the Week 8 and preliminary Week 16 results, QBECO SSI appears safe and well-tolerated and demonstrates consistently positive trends ...


21.03.2016

RespireRx Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase 2A Clinical Trial by March 31, 2016

GLEN ROCK, NJ -- (Marketwired) -- 02/29/16 -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (OTC QB: RSPI as of January 11, 2016; previously OTC QB: CORX) ("RespireRx" or the "Company"), a leader in developing medicines for respiratory disorders, particularly sleep apnea and drug-induced respiratory depression, announced today that it has received notice that the U.S. Food and Drug Administration (the "FDA") has removed the clinical hold on the Company''s ...


29.02.2016

IlluminOss Medical to Exhibit Its Groundbreaking Fracture Repair System at AAOS 2016

EAST PROVIDENCE, RI -- (Marketwired) -- 02/18/16 --, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair. The IlluminOss System is the world''s first and only system of its kind and offers significant advantages for the treatment of osteoporotic and pathologic fractures.IlluminOss Medical will be exhibiting its at . The system utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bon ...


18.02.2016

Novaseek Research Wins Pistoia Alliance President''s Startup Challenge 2015

BOSTON, MA -- (Marketwired) -- 02/17/16 -- Novaseek Research today announced that it is a winner of the inaugural 2015 Pistoia Alliance President''s Startup Challenge.The Pistoia Alliance is a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D. The Startup Challenge 2015 panel of expert judges, drawn from the Pistoia Alliance''s membership, evaluated more than 30 st ...


17.02.2016

Cromos(TM) Pharma Opens a Representative Office in Hungary

BUDAPEST, HUNGARY -- (Marketwired) -- 01/11/16 -- , an international full-service CRO, has announced today that it has opened a representative office in Budapest, Hungary."With a population of 10 million people, the highest standard of medical care and great investigator and patient engagement, Hungary exemplifies an excellent setting for global clinical research," said , CEO of "This development comes on the heels of our and is in line with overarching strategy to expand its ...


11.01.2016

Qu Biologics Closes Oversubscribed Financing; Crohn''s Disease Phase 2 Clinical Trial Results in First Quarter 2016

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 12/23/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune response, announced it has closed an oversubscribed private financing of CDN$3.5 million bringing the total private equity capital raised to CDN$19 million to date.Dr. Hal Gunn, CEO of Qu Biologics commented, "We are pleased with the high level of interest from private equity investors who clearly sha ...


23.12.2015

Hound Labs, Inc. Announces Major Breakthrough in Breath-Based Marijuana Measurement and Detection; Start of Clinical Trials

OAKLAND, CA -- (Marketwired) -- 12/02/15 -- , announced today a scientific breakthrough that allows the company to detect and measure the level of tetrahydrocannabinol (THC) in breath. Hound Lab, Inc.''s proprietary technology will provide, for the first time, the measurements necessary to help determine if an individual is impaired from recent marijuana use. Working in conjunction with scientists at the University of California, Berkeley, Hound Labs, Inc. is now optimizing the techno ...


02.12.2015

Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn''s Disease

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 11/24/15 -- , a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has completed enrollment of its QBECO-01 Crohn''s disease clinical trial, with top-line data expected in late 1Q 2016.Qu Biologics'' QBECO-01 is a 68-patient Phase 1/2 randomized, double-blind, placebo-controlled clinical trial in patients with moderate-to-sev ...


24.11.2015

Cromos(TM) Pharma announces the launch of "No Patients = No Payments" initiative

PORTLAND, OR -- (Marketwired) -- 10/28/15 -- , an international full-service CRO is strengthening its message of being able to deliver unparalleled patient recruitment with a disruptive initiative.This approach takes the risk sharing model to a new level by structuring agreements with biotech and Pharma companies in a way that allows sponsors to pay for the results that has promised from the outset."This is not a gimmick," said , CEO. "We arrive at timelines and recruitment nu ...


28.10.2015

Novaseek Research Receives Start up Challenge Award From the Pistoia Alliance

BOSTON, MA -- (Marketwired) -- 10/14/15 -- Novaseek Research, an innovator in clinical data and biospecimens for research, today announced that it was selected as a finalist for the prestigious Pistoia Alliance President''s Startup Challenge 2015. Novaseek provides life science industry and academia with access to real-world real-time human biospecimens and associated clinical data in compliance with HIPAA.The Pistoia Alliance is a global, not-for-profit alliance of life science compa ...


14.10.2015

Novaseek Research Launches Clinical Data Network for Research (CDNR) Platform

BOSTON, MA -- (Marketwired) -- 10/01/15 -- Novaseek Research today unveiled the Clinical Data Network for Research (CDNR) platform, the industry''s first comprehensive platform providing researchers in the life science industry and academia with access to real-world real-time clinical patient data and human biospecimens in compliance with HIPAA.Access to data and biospecimens is essential to understanding diseases and developing novel therapies, especially in the era of precision medi ...


01.10.2015

Qu Biologics Granted U.S. Patent for Use of Staphylococcus Aureus-Based Immunotherapies to Treat Melanoma

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/29/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today that it has been granted U.S. Patent No. 9,107,864 by the U.S. Patent and Trademark Office. The granted patent, which issued on August 18, 2015, covers the use of Staphylococcus aureus (staph or S. aureus) bacterial components to treat melanoma.Qu Biologics has developed ...


29.09.2015

Oracle Health Sciences Adds 93 Emerging Biopharmaceutical Customers

REDWOOD SHORES, CA -- (Marketwired) -- 09/29/15 -- Oracle (NYSE: ORCL)Emerging biopharmaceutical organizations face a growing number of regulatory requirements and, due to increased competition(1), acute pressure to speed time to market. Today, Oracle Health Sciences announced that 93 of these emerging biopharma organizations worldwide have become new customers in the past year, adopting Oracle Health Sciences solutions to succeed in this rapidly evolving market and deliver drugs to patients fa ...


29.09.2015

Insight Genetics Launches Insight RET Screen(TM), a Novel Solution for Biomarker-Driven Lung Cancer

NASHVILLE, TN -- (Marketwired) -- 09/02/15 -- Insight Genetics, Inc. today announced the launch of its Insight RET Screen™, a Clinical Laboratory Improvement Amendments (CLIA)-validated assay available through , that detects oncogenic RET (Rearranged during Transfection) expression in non-small cell lung cancer (NSCLC) patients. The Insight RET Screen is a qPCR assay that detects RET expression driven by chromosomal fusions regardless of the fusion partner.The current standard in diagnostic ass ...


02.09.2015

Cromos(TM) Pharma Opens a Representative Office in Prague, Czech Republic

PRAGUE, CZECH REPUBLIC -- (Marketwired) -- 08/05/15 -- , an international full-service CRO has announced today that it has opened a representative office in Prague, Czech Republic." has been managing clinical trials in Central and Eastern Europe for several years utilizing home-based project managers and monitors and we feel that the time has come to strengthen our territorial presence by opening a fully operational office in the heart of Central Europe," said , CEO. "Establishi ...


05.08.2015

Cell MedX Corp. (CMXC) Initiates Discussions With Industry Specialists at Worrell Design

LAS VEGAS, NV -- (Marketwired) -- 08/04/15 -- (OTCQB: CMXC) ("Cell MedX" or the "Company") a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to advise of entry into discussions with noted multiple award-winning international product design firm, Worrell Design Inc. ("Worrell").Founded in 1976, Worrell, headquartered in Minneapolis, Minnesota, is a p ...


04.08.2015

Qu Biologics Begins Phase 2 Clinical Trial in Ulcerative Colitis

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/28/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has initiated a .Qu Biologics'' clinical trial in ulcerative colitis has been initiated at the GI Research Institute in Vancouver, the first of at least four clinical trial sites in Canada. In the coming weeks, three additional sites will open in Edmonton, Calgary and ...


28.07.2015

Cell MedX Corp. (CMXC) Advances Development Timeline

LAS VEGAS, NV -- (Marketwired) -- 07/20/15 -- (OTCQB: CMXC) ("Cell MedX" or the "Company") an early development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes is pleased to update the timeline of its previously announced clinical trials regarding its innovative and proprietary technology branded under the trade name e-Balance.Dr. John Sanderson, Cell MedX Chief Medical Officer, has ...


20.07.2015

IlluminOss Medical Announces the Successful Treatment of First U.S. Patients With Innovative Light-Curable Bone Stabilization System

EAST PROVIDENCE, RI -- (Marketwired) -- 06/23/15 -- , a commercial stage medical device company focused on minimally invasive orthopaedic fracture repair, today announced that the first two U.S. patients have been treated through in collaboration with Cabell-Huntington Hospital and the Marshall Clinical Research Center as part of its U.S. Lightfix clinical trial for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma.The surgeries were performed by Fel ...


23.06.2015

Oracle Health Sciences InForm Cloud Service 6.1 Helps Life Sciences Organizations Accelerate Study Start-Up and Expand Risk-Based Monitoring Precision

WASHINGTON, DC -- (Marketwired) -- 06/16/15 -- DIA 2015 -- Oracle Health Sciences (NYSE: ORCL) today announced the availability of . The latest release of the Oracle Health Sciences InForm data capture and management platform provides trial sponsors and contract research organizations (CROs) with a complete, integrated solution designed to accelerate trial timelines, lower costs, deliver higher data quality, and reduce risk.The Oracle Health Sciences InForm Cloud Service 6.1 platform supports t ...


16.06.2015

YourEncore eBook and Infographic Highlight 10 Trends Shaping the Pharmaceutical Industry

INDIANAPOLIS, IN -- (Marketwired) -- 06/11/15 -- The PDUFA VI renewal cycle (and other regulatory policies), rising development and prescriptions costs, and potential supply chain vulnerabilities are a few of the trends impacting the pharmaceutical industry, according to a new eBook and infographic from YourEncore (), a company that helps firms in the , and industries solve complex innovation, compliance and productivity challenges. ."" eBook details 10 of the most pressing trends t ...


11.06.2015

Medical Device Company ZetrOZ and Clinical Research Partners Present Positive Results of NIH-Funded Clinical Studies at IEEE and World Physiotherapy Congress

TRUMBULL, CT -- (Marketwired) -- 05/04/15 -- ZetrOZ announced of its device (Long Duration, Low Intensity Therapeutic Ultrasound Intervention for Osteoarthritis Pain Management) at The Institute of Electrical and Electronics Engineers, Inc. (IEEE) bioengineering conference. early this year and are being presented at The World Physiotherapy Congress in Singapore this week.Results from the sam pilot studies show:Significant decrease in pain, as measured by a visual analog scale for pain (phase ...


04.05.2015

elluminate(R), eClinical Solutions Clinical Data Repository, Recognized by Independent Panel as One of the Most Innovative Life Sciences Products

MANSFIELD, MA -- (Marketwired) -- 04/30/15 -- , LLC, a leading provider of data management services and technologies, today announced that its ® clinical data repository has been featured in the April 2015 edition of PhamaVOICE magazine, which shines a light on the innovators and innovations that are changing the life sciences industry.The elluminate® platform helps life science companies integrate and standardize clinical and operational data from multiple sources, and allows users to perform ...


30.04.2015

Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn''s Disease Clinical Trial

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/24/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn''s disease clinical trial.Qu Biologics'' Crohn''s disease clinical trial is a randomized, placebo-c ...


24.04.2015

IlluminOss Medical Appoints Amy Orlick Berman as Vice President of Clinical Affairs

EAST PROVIDENCE, RI -- (Marketwired) -- 04/21/15 -- , a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced the appointment of Amy Orlick Berman as the company''s vice president of clinical affairs. Berman brings almost two decades of clinical affairs experience and has extensive expertise leading global research programs from inception through product approval. In her new position, she will be responsible for the global cl ...


21.04.2015

Biopharma Summit Set for May 12 on Re-Engineering Clinical Trials to Improve Drug Development and Performance

BOSTON, MA -- (Marketwired) -- 04/21/15 -- Responding to the mounting challenges of highly inefficient and costly clinical trials, which have stymied R&D productivity, the Tufts Center for the Study of Drug Development and ICON plc will host a one-day Biopharma Summit May 12 in Washington, DC, to outline innovative approaches and insights to "fixing the clinical trial conundrum.""There is widespread agreement across the pharmaceutical and biotech industry that the clinical tr ...


21.04.2015

Gastric Infections Arrested by LecSmart: Additional Human Trials Are About to Get Underway at Major University

CARSON CITY, NV -- (Marketwired) -- 04/13/15 -- LecSmart is a specialized powder extract concentrate, derived from wheat grain, which has been developed to control harmful microbes in the stomach and support gastrointestinal health.The performance of LecSmart has been evaluated in ongoing open human clinical trials at a gastroenterology center in Ventura, CA. Use of LecSmart appears to markedly decrease patient symptoms and improve lab outcomes. Published test results are pending.Additional hum ...


13.04.2015

Cell MedX Corp. (CMXC) Announces Additional Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial

LAS VEGAS, NV -- (Marketwired) -- 04/13/15 -- Cell MedX Corp. (OTCQB: CMXC), (the "Company") is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Ongoing metabolomic analyses of the samples have yielded additional insights into the immediate metabolic alterations brought about by a single e-balance technology ...


13.04.2015

Intrinsic Imaging Awarded Phase II Clinical Trial for Treatment of Glioblastoma Multiforme (GBM)

BOSTON, MA and SAN ANTONIO, TX -- (Marketwired) -- 04/09/15 -- Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant, imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with glioblastoma multiforme (GBM).Glioblastoma multiforme (GBM) is the most common and most aggressive malignant type of primary brain tumor (gliomas). With the exception of the brainstem gliomas, g ...


09.04.2015

Sunesis Pharmaceuticals Inc.''s CEO Daniel Swisher Interviewed by The Life Sciences Report

SAN FRANCISCO, CA -- (Marketwired) -- 04/02/15 -- Cancers are among today''s most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this , Daniel N. Swisher Jr., president and CEO of (NASDAQ: SNSS), describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides addit ...


02.04.2015

ePatientFinder Joins Greenway Online Marketplace for Comprehensive Health IT Solutions

AUSTIN, TX -- (Marketwired) -- 04/01/15 -- today announced it has joined the of value-added partners for users of Greenway''s integrated electronic health record (EHR) and practice management solutions.Being named a Marketplace-approved partner signifies cooperative efforts between ePatientFinder and Greenway to provide comprehensive, mission-critical health IT solutions that support the delivery of high-quality, cost-effective care.ePatientFinder, a leading clinical trial patient r ...


01.04.2015

OmniComm Systems Announces Innovative New Release of TrialMaster(R) EDC

FORT LAUDERDALE, FL -- (Marketwired) -- 04/01/15 -- OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces the general availability of release 4.2.1 of TrialMaster, its flagship product for Electronic Data Capture (EDC). This release provides new capabilities to capture audit trail information for electronic source data, dramatic productivity enhancements in the automated generation of SDTM datasets, the ability for sites in ...


01.04.2015

Intrinsic Imaging Awarded Phase II Clinical Trial for Treatment of Advanced Squamous Cell Carcinoma (SCC)

BOSTON, MA and SAN ANTONIO, TX -- (Marketwired) -- 03/31/15 -- , an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with advanced squamous cell carcinoma (SCC).Throughout this trial, Intrinsic Imaging will provide comprehensive imaging including, but not limited to, protocol and imaging charter development, site qualification, sit ...


31.03.2015

Qu Biologics Granted U.S. Patent for Use of E. coli to Treat Crohn''s Disease

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 03/31/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,980,279 relating to the use of immunotherapies derived from components of E. coli to treat Crohn''s disease.The allowed claims of the patent, which issued on March 17, 2015, cover the use of ...


31.03.2015

Veloxis Pharmaceuticals Chooses TrialMaster(R) EDC for Risk-Based Monitoring

FORT LAUDERDALE, FL -- (Marketwired) -- 03/11/15 -- OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, today announced that after a rigorous evaluation process of various commercially available EDC technologies, Veloxis selected TrialMaster EDC to run its Phase IV clinical studies.TrialMaster''s risk-based monitoring capability was a significant factor in the selection decision. The ability to collect and utilize many typ ...


11.03.2015

Intrinsic Imaging Awarded Interventional Medical Device Trial for Prevention of Pulmonary Emboli

BOSTON, MA and SAN ANTONIO, TX -- (Marketwired) -- 03/03/15 -- , an , and certified, medical imaging core lab specializing in providing for clinical trials, announced today that it has been awarded a clinical trial to study an interventional medical device designed for the prevention of pulmonary emboli.Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site traini ...


03.03.2015

OmniComm Systems(R) TrialOne(R) Suite Selected by ICON for Phase I Clinic Automation

FORT LAUDERDALE, FL -- (Marketwired) -- 03/03/15 -- OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, today announced the signing of a multi-year agreement with ICON for OmniComm Systems'' market leading TrialOne technology for Phase I clinic automation. ICON is one of the world''s largest contract research organizations (CROs) with around 10,600 employees in 38 countries. ICON provides drug development solutio ...


03.03.2015

Intrinsic Imaging Reports Exceptional Customer Satisfaction Survey Results for 2014 Fiscal Year

BOSTON, MA and SAN ANTONIO, TX -- (Marketwired) -- 02/26/15 -- , an FDA audited, and certified, medical imaging core lab specializing in providing for clinical trials, today announced the results of its annual Customer Satisfaction Survey for the fiscal period ending December 31st, 2014.Intrinsic Imaging offers Sponsors a wealth of therapeutic and operational expertise to best optimize the management and analysis of medical images in support of Phase I, II and III clinical trials in support ...


26.02.2015

Noted HIT Thought Leader Justin Barnes Takes on Advisory Role With ePatientFinder, the EHR-Driven Patient Recruitment Solution

AUSTIN, TX and ATLANTA, GA -- (Marketwired) -- 02/26/15 -- , which provides a platform that empowers physicians to connect their patients to life-changing clinical trial opportunities, announced today that HIT expert is joining the company in an advisory capacity."Justin has an extraordinary depth of expertise and knowledge in the EHR space, which he combines with a strong entrepreneurial spirit and background," said Tom C. Dorsett, President and CEO of ePatientFinder. "His indu ...


26.02.2015

Cromos(TM) Pharma Launches Cardiorus, a Premier Cardiology and Cardiothoracic Surgery Site Research Organization

MOSCOW, RUSSIA -- (Marketwired) -- 02/26/15 -- , an international full-service CRO announced today that it launched , a cardiology and cardiothoracic surgery site research organization (SRO) with its clinical base being at the Bakoulev Scientific Center in Moscow, Russia."The launch of gives us unprecedented capabilities to scale up both cardiology and cardiothoracic surgery drug and device studies," said Dr. Vlad Bogin, MD, FACP, company''s CEO. "We''ve been ...


26.02.2015

European Group for Research in Schizophrenia Selects OmniComm Systems(R) TrialMaster(R) Risk-Based & Centralized Monitoring With Auto-Redaction to Reduce Monitoring Costs

FORT LAUDERDALE, FL -- (Marketwired) -- 02/24/15 -- OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces that the European Group for Research in Schizophrenia (EGRIS) has selected TrialMaster electronic data capture (EDC) technology with risk-based and centralized monitoring for its European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). The EULAST trial will span 16 countries, involve 45 investigator sites, en ...


24.02.2015

ePatientFinder Completes $2.58 Million Series A Equity Financing

AUSTIN, TX -- (Marketwired) -- 02/10/15 -- , Inc. has raised a total of $2.58 million in Series A equity financing through Parsons & Whittemore alongside a group of angel investors. ePatientFinder provides a platform that connects its pharmaceutical, medical device and Contract Research Organization (CRO) clients with a network of clinics, hospitals and ACOs for the purpose of identifying and enrolling patients in clinical trials.The funds will be used for the expansion of the provider netw ...


10.02.2015

OmniComm Systems Appoints General Manager of China; Mr. Feng Cheng Focuses on Expanding Growth and Business Operations

FORT LAUDERDALE, FL -- (Marketwired) -- 02/09/15 -- OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces the appointment of Mr. Feng Cheng as general manager of OmniComm, China. Mr. Cheng will lead OmniComm''s long-term regional strategy, identifying and developing business expansion and growth initiatives.Recent market research has estimated that the Asia-Pacific region is poised to grow at CAGR of 19.5% in the n ...


09.02.2015

OmniComm Systems(R) Acquires IRT Technology From ClinQuest

FORT LAUDERDALE, FL -- (Marketwired) -- 02/06/15 -- OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces the acquisition of the interactive response technology (IRT) assets from ClinQuest, a leading global healthcare product development service provider. The solution will be branded as IRTMaster and will allow OmniComm to offer a completely integrated IRT and electronic data capture (EDC) solution, something that OmniComm c ...


06.02.2015

Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/04/15 -- , a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune function in the targeted diseased organ, announced that it has enrolled the first two trial participants into its Phase 2a clinical trial in non-small cell lung cancer.Qu Biologics'' CEO Dr. Hal Gunn commented, "We believe QBKPN SSI represents a promising approach to treating lung cancer by r ...


04.02.2015

Qu Biologics Launches Phase 2a Clinical Trial for Non-small Cell Lung Cancer (NSCLC)

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 01/20/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune function in the targeted diseased organ, announced that it has initiated a Phase 2a clinical trial in non-small cell lung cancer to study QBKPN SSI investigational treatment.The trial is a Phase 2a Open Label, Single-Arm, Exploratory Study to evaluate the immunological effects and safety, tolerability and ...


20.01.2015

eClinical Solutions Releases Newest Version of elluminate(R) for Clinical Data Aggregation, Standardization, and Analytics

MANSFIELD, MA -- (Marketwired) -- 01/20/15 -- , LLC, a leading provider of data management services and technologies, today announced the release of the latest version of their end to end clinical data repository and analytics platform, ®.The elluminate® platform integrates and standardizes clinical and operational data, regardless of source, to enable advanced analytics and adhoc reporting capabilities. This release enhances the ability to visualize operational data such as metrics, audit trai ...


20.01.2015

BRANY Launches Protocol Builder(TM) for Investigator-Initiated Clinical Trials

LAKE SUCCESS, NY -- (Marketwired) -- 01/20/15 -- BRANY has announced the launch of Protocol Builder™, a first-of-its-kind solution to assist researchers in the development of investigator-initiated clinical trials protocols. This web-based application, accessible from any desktop and iPad tablet, is designed to provide expert guidance and a step-by-step process to make development faster and less onerous. Resources necessary to navigate the elaborate regulatory infrastructure that surrounds cl ...


20.01.2015

OmniComm Systems(R) Announces 141% YOY Growth in Total Contract Value

FORT LAUDERDALE, FL -- (Marketwired) -- 01/16/15 -- OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces record growth in total contract value for 2014. Total contract value grew over 141% from 2013. A significant portion, 33%, of total contract value, came from companies that are within the 10 largest global contract research organizations (CRO) and pharmaceutical companies. The company experienced healthy year-over-year ...


16.01.2015

OmniComm Systems(R) Recognizes Excellence in Clinical Research and Development at Innovation Forum 2014

FORT LAUDERDALE, FL -- (Marketwired) -- 12/19/14 -- OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, recognizes excellence in innovation at OmniComm''s 4th annual Innovation Forum customer summit.The two-day event provided a forum for OmniComm customers to network, share current innovations, best practices and demonstrate the transformative impact of OmniComm''s technology on clinical development and research ...


19.12.2014

eClinical Solutions Achieves Accreditation on Medidata Rave(R) Safety Gateway

MANSFIELD, MA -- (Marketwired) -- 12/17/14 -- eClinical Solutions, LLC, an industry leading provider of end to end data management services and technologies, today announced their accreditation to customize and support the Medidata Rave® Safety Gateway.The Rave Safety Gateway is an extension to the Medidata Rave electronic data capture (EDC) and clinical data management (CDM) solution. The Rave Safety Gateway provides clinical research sponsors and contract research organizations with a more ef ...


17.12.2014

Cromos Pharma Launches Risk-Sharing Partnerships Program With Biotech and Pharma Companies

PORTLAND, OR -- (Marketwired) -- 12/15/14 -- , an international full-service CRO announced today the implementation of a risk-sharing platform partnering with biotech, pharma and device companies that have promising drug, biologics or medical device technologies. offers several unique business partnership algorithms through its risk-sharing model, including clinical research program conduct in exchange for equity or licensing opportunities."I have been intimately involved in the formation ...


15.12.2014

Qu Biologics Welcomes Gastroenterologist Dr. Remo Panaccione to IBD Advisory Team

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 12/04/14 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, is pleased to welcome gastroenterologist to its Inflammatory Bowel Disease (IBD) advisory team.Qu Biologics'' IBD advisory team provides guidance and oversight of Qu Biologic''s IBD studies, including a of its investigational treatment, QBECO SSI, for Crohn'� ...


04.12.2014

OmniComm Systems(R) Announces 135% YOY Growth in Total Contract Value Through Q3 2014

FORT LAUDERDALE, FL -- (Marketwired) -- 11/26/14 -- OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, today announced that Q3 2014 total contract value was up by over 260% from the same period in 2013. Year-over-year total contract value grew over 135%. New clients accounted for over 73% of all new contracts through Q3 2014 and 20% of all contracts had a term life in excess of 30 months. The record contract growth is attributed t ...


26.11.2014

Larix, Denmark''s Full Service Contract Research Organization, Selects OmniComm''s(R) TrialMaster(R) Electronic Data Capture Solution

FORT LAUDERDALE, FL -- (Marketwired) -- 11/20/14 -- OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, is pleased to announce that Larix; a full service Danish contract research organization (CRO) offering statistics, data management and medical writing, has selected TrialMaster electronic data capture (EDC) as its standard EDC technology. Located in the heart of the Denmark''s Medicon Valley, one of Europe''s ...


20.11.2014

IlluminOss Medical Announces Conditional FDA Approval for Clinical Trials of Groundbreaking Photodynamic Bone Stabilization System in the U.S.

EAST PROVIDENCE, RI -- (Marketwired) -- 11/18/14 -- , a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received conditional approval from the FDA to conduct a clinical trial for the treatments of impending and pathologic fractures in the humerus due to metastatic carcinoma. IlluminOss expects to begin enrolling clinical sites and initiate the trial shortly.IlluminOss'' is the world'� ...


18.11.2014

Cromos(TM) Pharma Launches Corium Research, a Premier Dermatology Site Research Organization

MOSCOW, RUSSIA -- (Marketwired) -- 11/18/14 -- Cromos™ Pharma, an international full-service CRO announced today that it launched Corium Research, a state of the art dermatology site research organization (SRO) comprised of 24 specialized dermatology medical centers and clinics in Moscow, Russia."Corium Research is an organic addition to the scope of services that are being provided by Cromos™ Pharma," said Dr. Vlad Bogin, MD, FACP, company''s CEO. "We''ve col ...


18.11.2014

Medical Research Leaders, Innovators and Investors Come to New York to Forge Partnerships, Speed Cures

WASHINGTON, DC -- (Marketwired) -- 11/05/14 -- On Nov. 16-18, nearly 1,000 medical research leaders, investors and decision-makers will come to New York City for the 6th annual meeting. Convened by , a Washington-based center of the Milken Institute, this unique conference brings together innovators from across all sectors of the medical research enterprise -- academic scientists, federal policymakers, biotechnology and pharmaceutical executives, life science investors, foundations and patient ...


05.11.2014

Qu Biologics'' Crohn''s Disease Clinical Trial Completes Independent Safety Review

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 10/29/14 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s immune system, announced that an independent Data Safety Monitoring Committee (DSMC) has reviewed the safety data generated from 30 patients (50% enrollment) from Qu Biologics'' current Crohn''s disease clinical trial and has recommended that the trial continue as planned with continued safety monito ...


29.10.2014

Revolutionary ePatientFinder Platform Empowers Physicians to Leverage Their EHR to Connect Patients With Clinical Trials

AUSTIN, TX -- (Marketwired) -- 10/29/14 -- Physicians searching for new and emerging treatment options for patients with a chronic disease now have an innovative, easy-to-use platform and service. is the first technology solution that helps physicians learn about clinical trial opportunities for their patients and easily identify patients who may benefit from taking part in a clinical trial.ePatientFinder is available at no cost to physicians and health organizations. ePatientFinder integrates ...


29.10.2014

Omicia Introduces Phevor to Boost Identification of Disease-Causing Gene Mutations

OAKLAND, CA -- (Marketwired) -- 10/28/14 -- Omicia, Inc., , today announced it is integrating Phevor™ (Phenotype Driven Variant Ontological Re-ranking tool) into its Opal product offering. Phevor, an algorithm co-developed by the University of Utah and Omicia, accelerates identification of disease-relevant variants in genomic sequences.Phevor is being integrated into Omicia''s Opal platform including with , a comprehensive Software-as-a-Service genomic interpretation platform that was ...


28.10.2014

Belgian Contract Research Organization, Business & Decision Life Sciences, Partners With OmniComm Systems(R)

FORT LAUDERDALE, FL -- (Marketwired) -- 10/28/14 -- OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of data management solutions for clinical trials, today announced a partnership with Business & Decision Life Sciences (BDLS), a contract research organization (CRO) and life sciences information technology consultancy headquartered in Brussels, Belgium. This partnership enhances OmniComm''s presence in key geographies as it continues to experience continued and sust ...


28.10.2014

Vista Partners Updates Coverage on CytoSorbents Corporation (ticker: CTSO); $0.50 Price Target

SAN FRANCISCO, CA -- (Marketwired) -- 10/22/14 -- announced today that it has updated coverage on (OTCQB: CTSO) ("The Company," or "CTSO"); and maintains its twelve month price target of $0.50. Ross Silver, Principal Analyst at Vista Partners, stated, "According to the Company, CytoSorbents'' flagship product is CytoSorb® which targets the treatment of life-threatening illnesses in the intensive care unit, such as sepsis, Ebola, trauma, burn injury, and many ...


22.10.2014

Radiant Sage Announces Corelab-in-a-Box Version 3.1

BELMONT, MA -- (Marketwired) -- 10/20/14 -- , a provider of on-demand clinical trial imaging infrastructure solutions, today announced the newest version of its Corelab-in-a-Box™ (CLIB) Clinical Trial Imaging Management technology solution. This new version provides sponsors with the key functionality of an imaging corelab in a web-based solution bringing security, efficiency, speed, and transparency to what was considered a black box industry. CLIB Version 3.1 has expanded its features for spe ...


20.10.2014

Top 10 Pharmaceutical Company Moves to OmniComm Systems''(R) OmniCloud(R)

FORT LAUDERDALE, FL -- (Marketwired) -- 10/20/14 -- OmniComm Systems, Inc. (OTCQB: OMCM), a global leading provider of clinical data management technology, was selected by a top 10 pharmaceutical company to migrate its on-premise clinical data management technology to OmniCloud (OmniComm''s clinical cloud technology platform). This is part of an overarching corporate initiative to migrate all clinical development enterprise applications to the cloud. This is the largest initiative of ...


20.10.2014

Top Research Collaborations Explain How They Are Speeding the Path to Cures

WASHINGTON, DC -- (Marketwired) -- 10/08/14 -- Thirty of the most creative, cross-sector collaborations in medical research will present their models to potential partners and funders at FasterCures'' sixth annual meeting, November 16-18 in New York City. Selected through a competitive proposal process, these partnerships are aimed at reducing the time and cost of getting new medical solutions from discovery to patients."The quality of our over 120 applicants -- more than twice ...


08.10.2014

MMRGlobal to Report Third Quarter Revenue Exceeding Biggest Year in Company History

LOS ANGELES, CA -- (Marketwired) -- 10/06/14 -- (OTCQB: MMRF) ("MMR" or the "Company") today announced that it will report third quarter revenues from all sources in excess of total revenues from its biggest year. The Health Information Technology and Biotechnology Company will report substantially more revenue than the $1.420 million reported from the entire calendar year of 2011, previously the biggest year in the Company''s history and which the Company has rec ...


06.10.2014

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00

SAN FRANCISCO, CA -- (Marketwired) -- 09/24/14 -- announced today that it has updated coverage on (OTCBB: SNGX), based in Princeton, New Jersey, and revised its twelve-month price target higher from $5.50 to $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in early 2015. The science behind the Company''s prospective therapies ha ...


24.09.2014

Leading In Vitro Diagnostics Company Selects OmniComm''s(R) TrialMaster(R) Electronic Data Capture Solution

FORT LAUDERDALE, FL -- (Marketwired) -- 09/17/14 -- OmniComm Systems, Inc. (OTCQB: OMCM), a global leading provider of clinical data management technology, is pleased to announce that a leading in vitro diagnostics (IVD) company has selected TrialMaster electronic data capture (EDC) to support its clinical evaluation of innovative IVD products for rapid identification and antibiotic susceptibility testing of infectious pathogens.Because IVD trials are significantly different from drug or biolog ...


17.09.2014

MMRGlobal Receives Significant Intellectual Property Milestone Payment

LOS ANGELES, CA -- (Marketwired) -- 09/17/14 -- (OTCQB: MMRF) ("MMR" or the "Company") today announced that it has received another significant milestone payment pursuant to an existing Non-Exclusive License Agreement (the "Agreement") pertaining to the Company''s biotech assets. Additional information regarding this milestone payment will be contained in the Company''s quarterly report on Form 10-Q for the quarter ending September 30, 2014. Th ...


17.09.2014

YourEncore Joins Global Alzheimer''s Platform; Jason Bork Appointed Project Management Lead

INDIANAPOLIS, IN -- (Marketwired) -- 09/16/14 -- YourEncore (), a company that helps , and solve complex innovation, compliance and productivity challenges, is loaning executive Jason Bork to the Global Alzheimer''s Platform to act as the group''s project management lead.was launched in February by the and the . GAP''s objectives are to reduce the time and costs of Alzheimer''s clinical trials by developing a patient registry infrastructure and a pre-q ...


16.09.2014

Qu Biologics Appoints Rashieda Gluck as Vice President, Clinical Operations

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 12/11/13 -- ., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to 'reboot' the body's immune system to treat cancer and autoimmune disease, announced it has appointed Rashieda Gluck as Vice President, Clinical Operations.As Vice President, Clinical Operations, Rashieda Gluck will lead development, execution and delivery of Qu Biologics' clinical trial programs.Qu Biologics Chief Executive O ...


11.12.2013



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 49


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.